Abstract
Our extensive efforts to develop inhibitors for human cathepsin L and SARS-CoV-2 main protease (Mpro) have led to the identification of a set of antiviral agents exhibiting superior efficacy compared to nirmatrelvir (synthesized in our laboratory and dubbed Neq1183). Preliminary studies on cytochrome P450 enzymes revealed that Neq1184 shows no activity, indicating that it is a superior ca…